Head-to-head evidence
Paliperidone palmitate (Erzofri) vs Risperidone (Rykindo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
In this trial, paliperidone palmitate (INVEGA SUSTENNA) served as the reference comparator against which an investigational competitor formulation, LY03010, was measured for pharmacokinetics; the study was open-label with no blinding, and no results have been posted.
Risperidone (Rykindo)
Marketed by Luye Pharma Group
NCT02055287 · Phase 1 · completed
A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Erzofri)'s landscape · Risperidone (Rykindo)'s landscape